Adamis announces pre-ind feedback from fda enabling advancement of tempol

Adamis pharmaceuticals announces pre-ind feedback from fda enabling advancement of tempol, a novel anti-inflammatory and anti-oxidant drug for the treatment of covid-19.adamis pharmaceuticals corp - fda has provided detailed comments regarding prospective use of tempol in a randomized placebo controlled trial.adamis pharmaceuticals corp - fda's response now allows adamis to proceed to next step of formally submitting an ind for tempol.adamis pharmaceuticals corp - fda's response allows co to begin formal applications for funding to governmental agencies to support clinical trial.
ADMP Ratings Summary
ADMP Quant Ranking